N/A N=439 Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)
Substance Use Disorders · HIV
Primary: Implementation Status — 12; 12; 12 milestones
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Ketamine Plus Lithium in Treatment-Resistant Depression
Depression
Primary: MADRS-S Score — 22.56; 23 units on a scale
Phase 1 N=19 Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in Cycle 1 for the Determination of the Maximum Tolerated Dose (MTD) of Volasertib — 0; 0; 1 Participants
N/A N=23 Humeral Shaft Pseudoarthrosis Treated With Bone Autograft Versus Platelet Rich Plasma
Pseudoarthrosis
Primary: Stans Scale — 2.7; 3.0 units on a scale
N/A N=12,378 Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Chronic Hepatitis B
Primary: Number of Participants With Adjudicated Overall Malignant Neoplasms — 331; 337 Participants — p=0.3553
Phase 1 N=5 Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 2 Participants
Phase 2 N=136 SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
Staphylococcal Infections
Primary: Percentage of Participants With At Least 1 Local Reaction Within 14 Days of Vaccination — 2.9; 20.6; 5.9; 29.4 Percentage of participants
N/A N=100 ADVANCE Direct Aortic Study
Aortic Stenosis · Valvular Heart Disease
Primary: All-cause Mortality — 4.4 Percentage of subjects
Phase 3 N=516 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
Cervical Dystonia
Primary: Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12) — -3.8; -4.0; -3.8…
Phase 1 N=32 A First Human Study of a Ferroportin Antibody
Healthy Volunteers
Primary: Number of Participants With Clinically Significant Adverse Effects — 7; 6; 5; 5 participants
N/A N=33 Mindfulness Intervention to Study the Neurobiology of Depression
Depression
Primary: Change in Children's Depression Rating Scale - Revised — 27.47; 28.00; 25.53; 31.86 units on a scale
Phase 1 N=30 Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD). — 0; 0; 3; 2 participants
N/A N=4,173 4 Pillars Toolkit for Adolescent Vaccination
Adolescent HPV Vaccine · Adolescent Influenza Vaccine
Primary: Change in Percentage of Cumulative HPV Series Initiation Vaccination Rates for Adolescents 11-17 Years of Age — 13.7; 10.1; 7.8; 5.7 percent change in vaccination rates…
Phase 1 N=43 A Study of LY3084077 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 0; 0; 0 participants
N/A N=228 Spouse READI (Resilience Education And Deployment Information) Post Deployment Telephone Support Groups
Spouses · Military Personnel · Coping Skills
Primary: Spouse Self-report of Anxiety — 7.9; 7.1; 7.9; 5.5 units on a scale